Clinical trials: Pulmonary Fibrosis, Interstitial Lung Disease
Radiation Pneumonitis
Risk Factors of Radiation Pneumonitis
A prospective observational study to evaluate clinical, dosimetrical, functional, and biological factors in predicting radiation pneumonitis.
- Trial name
- NCT00155909
- Where
- Taiwan
- Volunteers
- 53 people
- Sponsor
- National Taiwan University Hospital
Idiopathic Pulmonary Fibrosis
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
This study will evaluate the safety of the administration of a copper chelating agent, tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous treatment.
- Trial name
- NCT00189176
- Testing
- Tetrathiomolybdate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) and the 3 Minutes Sit-to-stand Test
This study is designed to evaluate the reproductibility and the performance of the 3 minutes sit-to-stand test in patients with idiopathic pulmonary fibrosis.
- Trial name
- ST2-IPF (NCT03268915)
- Testing
- 3 minutes sit-to-stand test
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Grenoble
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06588517
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Sarcoidosis, Pulmonary Fibrosis
The Influence of Personality on Pulmonary Fibrosis and Sarcoidosis
A number of studies have shown that the quality of life of two common interstitial lung diseases (ild), sarcoidosis and pulmonary fibrosis patients, is impaired and that fatigue is a substantial problem for those patients.
- Trial name
- NCT00504621
- Volunteers
- 450 people
- Sponsor
- Maastricht University Medical Center
Pulmonary Fibrosis of Any Cause, Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
Pulmonary Fibrosis Contact Registry
As the name states, contact registries securely store contact information from groups of reasonably well-characterized patients (or primary supporters/caregivers) who are interested in being informed about ongoing or future…
- Trial name
- NCT01935726
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases
Social distancing during the COVID-19 pandemic could lead to clinical and functional deterioration of people living with chronic respiratory diseases (CRD).
- Conditions
- Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, Asthma Chronic
- Trial name
- NCT04693975
- Where
- Brazil
- Volunteers
- 94 people
- Sponsor
- Universidade Estadual de Londrina
Pulmonary Fibrosis
An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology
The I-FILE study is a prospective multicenter, multinational observational study where the feasibility of a patient-led registry using home monitoring in patients with pulmonary fibrosis will be evaluated.
- Trial name
- I-FILE (NCT04304898)
- Testing
- Home spirometry
- Where
- 2 sites in Netherlands
- Volunteers
- 700 people
- Sponsor
- Erasmus Medical Center
Idiopathic Pulmonary Fibrosis (IPF)
D Vitamin and Alveolar Macrophages in Idiopathic Pulmonal Fibrosis
The goal of this observational study is to gain deeper insights into human macrophages and vitamin D, and their interplay, within Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT06909409
- Where
- Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Idiopathic Pulmonary Fibrosis
Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPF
Idiopathic pulmonary fibrosis (IPF) is a chronic and potentially fatal lung disease. As IPF progresses, patients become increasingly breathless with reduced exercise capacity and quality of life.
- Trial name
- NCT03360032
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Pulmonary Fibrosis, Breast Cancer
Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients
Two hundred and sixty patients with breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms.
- Trial name
- CONSET (NCT00896155)
- Testing
- Tamoxifen, Radiotherapy
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Hospital
Interstitial Fibrosis, Kidney Transplant; Complications
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard…
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection
- Trial name
- NCT05285878
- Testing
- Fingolimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT06003426
- Testing
- BMS-986278
- Where
- 390 sites in United States, Argentina and 31 more
- Volunteers
- 1,255 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, Interstitial Lung Disease
- Trial name
- NCT01203943
- Testing
- CC-930
- Where
- 22 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Celgene
Idiopathic Pulmonary Fibrosis
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and…
- Trial name
- NCT02552849
- Testing
- No intervention
- Where
- 26 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche
Lung Fibrosis
Pulmonary Outcomes on Patients With Lung Fibrosis
The pulmonary fibrosis is lung disease that occurs when lung tissue become damaged and scarred. The objectives of treatment are to improve symptoms and quality of life, and slow disease progression.
- Trial name
- NCT07088185
- Testing
- Routine medical care, Pulmonary rehabilitation
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- South Valley University
Pulmonary Fibrosis
Illness Expectations in Pulmonary Fibrosis
This study aims to delve into the constructs of illness beliefs and expectations among patients with Pulmonary Fibrosis, exploring how these beliefs and expectations may influence the treatment journey, including oxygen therapy…
- Trial name
- CAMFP (NCT06327360)
- Testing
- Psychological questionnaires
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS